Navigation Links
University of Minnesota study refutes belief that black men have more aggressive prostate cancer
Date:9/17/2007

A University of Minnesota study of prostate cancer tumors from Caucasian and African-American men has shown no evidence that the cancer is more aggressive in black men. Lead investigator Akhouri Sinha, a professor of genetics, cell biology, and development and research scientist at the Minneapolis VA Medical Center, said the belief that black mens tumors are more aggressive is based on studies that failed to match patients properly and used only indirect means to measure tumor aggressiveness. The work will be published in Anticancer Research Sept. 21 (vol. 27, issue 5A, pp. 3135-3142).

In previous studies of prostate tumors, those in black patients tended to be larger and at a more advanced stage, and black men had higher blood levels of prostate specific antigen (PSA), a substance produced by the prostate that, at high levels, points to the possibility of prostate cancer. But all these criteria are interrelated and could be the result of delayed diagnosis or medical care, Sinha said.

Previous studies showing differences in prostate cancers among races require re-evaluation because inconsistent criteria were used in selection of patients, he said. Our data shows that for patients receiving similar treatment, African-American patients are not following up with their doctors as opposed to Caucasians, and this difference is highly significant. Also, Caucasian patients are four times as likely to receive additional treatment after prostatectomy. Cancer does not discriminate on the basis of race, religion, national origin, or caste system, like people do. Invasiveness of prostate cancer is not race-dependent.

According to Sinha, what is needed is a comparison of the innate aggressiveness of tumors that have been matched by criteria relevant to a diagnosis of cancer as well as treatment after prostatectomy.

Drawing on the resources of the Minneapolis Veterans Affairs Medical Center, Sinha selected preserved slices of tumors from 130 surgery patients. From these he was able to match 25 black and 25 white patients according to age, Gleason grade (a pathologists measure of how advanced a prostate tumor is), clinical stage of the tumors and PSA levels before prostatectomy.

To determine how aggressive the tumors were, Sinha measured the levels of an enzyme that is essential for destroying membranes that keep cells in place. Called cathepsin B, the enzyme, if unchecked, carves out an escape route by which cancer cells can spread. He also measured the levels of a substance, known as stefin A, that inhibits cathepsin B. The ratio of the two substances in slices of prostate tumors gives a measure of how invasive, or aggressive, the tumors are. The most aggressive ones are characterized by a high ratio of cathepsin B to stefin A.

Results showed that the ratios were not significantly different in tumors of black and white men, all of whom had Gleason score 6 or 7 tumors, indicating moderate risk. The average ratios were 1.78 in black men and 1.59 in white men for Gleason score 6 tumors, and 1.49 in black men and 1.35 in white men of Gleason score 7 tumors. All these ratios were higher than the average ratio in control tissue taken from men with benign prostatic hyperplasia, a common, noncancerous enlargement of the gland.

Sinha said that previous studies had found differences between black men compared to white men and men of other races in terms of prostate cancer incidence, death rate, tumor volume, age, Gleason score and PSA levels. But other factors, such as level of medical care, economic status, access to medical care and nutrition undoubtedly contributed to those differences.

Our selection of patients, who received equal medical care at the Minneapolis Veterans Affairs Medical Center, minimized differences in prostate cancer of African-American and Caucasian patients, he said. Furthermore, previous studies did not include [enzymes like cathepsin B] as a factor to distinguish between African-American and Caucasian men, and, therefore, did not provide clues as to the biological basis of invasiveness and progression of prostate cancer.

Sinha stressed that his results must be confirmed by more expansive studies.


'/>"/>

Contact: Patty Mattern
matte016@umn.edu
612-624-2801
University of Minnesota
Source:Eurekalert

Related biology news :

1. University of Manchester makes made-to-measure skin and bones a reality using inkjet printers
2. New protein discovered by Hebrew University researchers
3. Next Generation Body Scanner Launched By The University Of Manchester
4. Roundup®highly lethal to amphibians, finds University of Pittsburgh researcher
5. Green catalyst destroys pesticides and munitions toxins, finds Carnegie Mellon University
6. University of Nevada, Reno research team discovers hormone that causes malaria mosquito to urinate
7. Carnegie Mellon University research reveals how cells process large genes
8. University of Delaware researchers develop cancer nanobomb
9. University of Arizona plant scientists to unravel maize genome
10. Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace
11. University of Utah to help build bionic arm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... Mass. , March 24, 2017 Agenus ... of immune checkpoint antibodies and cancer vaccines, today announced ... The 7 th  Annual William Blair and Maidstone Life ... Space Alexandria Center in New York, NY ... March 29 at 9:40 am: Robert ...
(Date:3/23/2017)... Diego, Calif. (PRWEB) , ... March 23, 2017 , ... Lajollacooks4u is proud to announce ... 2008, it has hosted corporate cooking challenges for companies around the world, such as Illumina, ... , Part of the reason for its increasing popularity is due to its new team ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)... March 23, 2017  GlobeImmune, Inc. today announced it ... sale of 12,835,490 shares of its common stock to ... companies. In connection with the sale of its common stock, ... and issue to GlobeImmune 200,000 shares, an estimated $2.0 ... "We are pleased to enter into this strategic ...
Breaking Biology Technology: